Betaxolol | Betaxolol tablets 20 mg 30 pcs.

Release form

Tablets.

Packing

Per pack 30 pcs.

Pharmacological action

Cardioselective beta1-blocker without internal sympathomimetic activity. It has a weak membrane stabilizing activity.

Has a hypotensive effect associated with a decrease in cardiac output and a decrease in peripheral vascular sympathetic stimulation.

When used in therapeutic doses, it does not have a cardiodepressive effect, does not affect glucose metabolism, does not reduce the bronchodilatory effects of beta-adrenergic agonists, and does not cause sodium retention in the body. It acts for a long time.

Topical application in the form of eye drops lowers increased intraocular pressure. Resorptive effect is negligible.

Indications

For systemic use: arterial hypertension.

For topical use in ophthalmology: chronic open-angle glaucoma, increased intraocular pressure, condition after laser trabeculoplasty.

Contraindications

Cardiogenic shock, severe chronic heart failure, AV block II and III degree, SSSU, sinoatrial blockade, sinus bradycardia, severe peripheral circulation disorders, hypersensitivity to betaxolol.

Use during pregnancy and lactation

During pregnancy and during lactation (breastfeeding), the use of betaxolol is possible only in cases where the intended benefits to the mother outweigh the possible risk to the fetus or child.

Special instructions

It is not recommended for use in bronchial asthma, chronic bronchitis with bronchial obstructive syndrome.

Used with caution in diabetes mellitus, suspected thyrotoxicosis, with a history of bronchial hyperreactivity, in patients with degree I AV block, Raynaud's syndrome, pheochromocytoma.

When administered orally for liver failure, as well as for renal failure (CC less than 20 ml / min), there is no need to adjust the dosage regimen, however, regular clinical observation is recommended during the first few days of treatment.

In the early days of treatment, the possibility of symptoms of heart failure in predisposed patients should be considered. Betaxolol withdrawal should be carried out gradually, especially in patients with coronary artery disease, angina pectoris.

Betaxolol does not affect the size of the pupil, therefore, with angle-closure glaucoma, the drug should be used only in combination with miotics. When a patient is transferred to betaxolol after treatment with several anti-glaucoma drugs, the latter are canceled gradually, at least 1 week per drug.

With the simultaneous use of betaxolol in the form of eye drops and beta-blockers inside, the development of additive effects both on the part of intraocular pressure and the manifestations of the systemic action of beta-blockers is possible.

Before carrying out a planned operation beta-blockers, incl. betaxolol should be discontinued.

Contactax should not be worn with topical betaxolol.

Betaxolol is not recommended in children.

Influence on the ability to drive vehicles and control mechanisms

Used with caution in patients whose activities require increased attention and rapid psychomotor reactions.

Composition

active ingredient:

betaxolol hydrochloride - 20 mg

excipients, including shell composition:

lactose monohydrate,

sodium starch glycolate,

silicon dioxide colloidal anhydrous, sroldkl E 171,

talc,

macrogol / PEG 3350,

lecithin (soy).

Dosage and administration of

For systemic use when taken orally, 20 mg once a day.

For patients undergoing permanent hemodialysis or peritoneal dialysis, the initial dose is 10 mg / day, the time of taking betaxolol is set regardless of the mode of dialysis sessions.

For topical use in ophthalmology - 1 drop 2 times / day in the affected eye.

During the first month, therapy is carried out under the control of the level of intraocular pressure, in the future the frequency of measurement of intraocular pressure is determined individually.

In the case of betaxolol after the previous treatment with another similar drug, the dosage regimen is set individually.

Side effects of

From the cardiovascular system: at the beginning of treatment - AV block, sinus bradycardia, arterial hypotension, heart failure, Raynaud's syndrome.

From the digestive system: rarely - abdominal pain, nausea, vomiting.

From the side of the central nervous system and peripheral nervous system: at the beginning of treatment - asthenia, paresthesia of the extremities, sleep disturbances, depression, drowsiness, dizziness.

From the respiratory system: rarely - bronchospasm.

Allergic reactions: rarely - psoriasis-like skin manifestations.

Local reactions: when applied in the form of eye drops immediately after instillation, short-term discomfort in the eyes is possible, sometimes lacrimation is rare - decreased sensitivity of the cornea, erythema, pruritus, spotted staining of the cornea, keratitis, anisocoria, photophobia.

Drug Interactions

When used simultaneously with adrenergic agonists, xanthine derivatives, the effectiveness of betaxolol decreases.

With simultaneous use with antacids and antidiarrheal agents, it is possible to reduce the absorption of beta-blockers.

When used concurrently with antihypertensive agents, the antihypertensive effect is enhanced.

With the simultaneous use of halogen-containing agents for inhalation anesthesia, an increase in negative inotropic action is possible.

With the simultaneous use of non-depolarizing muscle relaxants, an increase in their duration of action is possible.

With the simultaneous use of NSAIDs, corticosteroids, the antihypertensive effect of betaxolol is reduced.

With the simultaneous use of cardiac glycosides, increased bradycardia is possible.

With the simultaneous use of tricyclic antidepressants (imipramine) blood pressure decreases, there is a risk of orthostatic hypotension.

With the simultaneous use of amiodarone, verapamil, diltiazem, beta-blockers for topical use in glaucoma may increase the negative inotropic effects and impaired conductivity.

With the simultaneous use of lidocaine, the concentration of lidocaine in the blood plasma increases.

With simultaneous use with drugs that deplete catecholamine reserves (including with reserpine), an increase in the hypotensive effect and bradycardia is possible.

With simultaneous use with sulfasalazine, the concentration of betaxolol in the blood plasma increases.

Deystvuyuschee substances

Betaxolol

Terms and conditions

prescription

dosage form

tablets

Moscow Endocrine Plant, Russia